Site Editor

David S. Ettinger, MD, FACP, FCCP

Advertisement

Advertisement

News

Study Finds Link Between Guideline Adherence and Survival in NSCLC

News

Atezolizumab Plus Bevacizumab: A Potential Option for Certain Patients With Nonsquamous Lung Cancer

News

Immune Checkpoint Inhibitors and Lung Cancer: Tumor Vasculature–Based Imaging Biomarker

Medical Literature

RNA Modification and Tumor Immunity in Lung Cancer: Predicting Outcomes With Neoadjuvant Immunotherapy

News

Immune Checkpoint Inhibitors and Lung Cancer: Tumor Vasculature–Based Imaging Biomarker

Medical Literature

PEARLS/KEYNOTE-091: Adjuvant Pembrolizumab in Completely Resected Stage IB–IIIA NSCLC

Medical Literature

Can Artificial Intelligence Be Used to Predict the Presence of ALK Rearrangement in Lung Cancer?

Qinjin Fan, PhD, on Mortgage Discrimination and a Potential Link to Less Guideline-Concordant Care in Lung Cancer

Pranshu Mohindra, MD, MBBS, on Considering Intensity-Modulated Proton Therapy–Based Reirradiation for Patients With NSCLC

View More

Advertisement

JNCCN Spotlights

Dabrafenib + Trametinib (Tafinlar + Mekinist)

Crizotinib (Xalkori)

(UPDATE) Pembrolizumab (Keytruda) in NSCLC

(UPDATE) Nivolumab (Opdivo) in NSCLC

(UPDATE) Afatinib (Gilotrif)

Sotorasib

View More

More

News

Immune Checkpoint Inhibitors and Lung Cancer: Tumor Vasculature–Based Imaging Biomarker

Atezolizumab Plus Bevacizumab: A Potential Option for Certain Patients With Nonsquamous Lung Cancer

SITC 2022: Is Immunotherapy Feasible for Patients Living With HIV and NSCLC?

Neoadjuvant Atezolizumab: Focus of National Study in Resectable NSCLC

I-ELCAP Trial Shows Long-Term Survival Benefits of Lung Cancer Screening

FDA Approves Pembrolizumab as Adjuvant Therapy for NSCLC

Adding a Novel Antibody to Anti–PD-1 Immunotherapy for Metastatic NSCLC

Study Finds Link Between Guideline Adherence and Survival in NSCLC

View More

Advertisement

Published

Medical Literature

Common Genes Associated With Overall Survival in NSCLC

Trends in the Cost of Agents Used to Treat Metastatic NSCLC

Early Research May Support Targeting PGM3 in Lung Cancer With Concurrent Mutations

Can Driver Genetic Alterations Predict Survival in Advanced Lung Adenocarcinoma?

View More

Ongoing

CE Activities

A Phase II/III Study of N-803 (ALT-803) Plus Pembrolizumab vs Standard of Care in Stage IV or Recurrent NSCLC

A Randomized, Open-label, Phase II Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-Naive Subjects With Advanced or Metastatic PD-L1 High NSCLC Without Actionable Genomic Alterations

A Phase III Double-Blind Trial for Surgically Resected Early Stage NSCLC: Crizotinib vs Placebo for Patients With Tumors Harboring the ALK Fusion Protein

A Randomized Phase II Trial of Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I NSCLC With Primary Tumors Between 1 and 4 cm:

View More

Available

Clinical Trials

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

LATIFY: Ceralasertib Plus Durvalumab vs Docetaxel in NSCLC Whose Disease Progressed on or After Prior Anti–PD(L)1 Therapy and Platinum-Based Chemotherapy

A Phase III, Randomized, Placebo-Controlled Clinical Study of SBRT With or Without Pembrolizumab in Participants With Medically Inoperable NSCLC (KEYNOTE-867)

Fox Chase Cancer Center

View More

Resources

For Your Patients

The American Lung Association

Bonnie J. Addario Lung Cancer Foundation

Caring Ambassadors Program

Dusty Joy Foundation

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2023 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.